Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals

    • Most Recent Events

    • 01 Feb 2023 Results of post hoc analysis from 6 studies(n=209 from NCT01859988, NCT02277743, NCT02277769, NCT03054428, NCT02260986, NCT02755649) assessing Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis published in the JAMA Dermatology
    • 03 Dec 2021 Results comparing (n=2932) hospitalization rates (all-cause and AD-related) of adults with atopic dermatitis treated with dupilumab versus control by post hoc analysis of 7 RCTs (NCT01548404, NCT02277743, NCT02277769, NCT01859988, NCTO2210780, NCT02755649 and NCT02260986), presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 28 Sep 2019 Results (n=250) of sub-analysis of three studies (AD-1021; LIBERTY AD SOLO 1 and LIBERTY AD CHRONOS) assessing efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis, published in the British Journal of Dermatology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top